A daily 40-mg dose of atorvastatin for 12 months significantly cut incident cardiac dysfunction in patients with lymphoma receiving anthracycline treatment.
Citing a lack of efficacy data, the FDA has declined to approve omecamtiv mecarbil (Cytokinetics) for treatment of adults with chronic heart failure with reduced ejection fraction.
The Society for Cardiovascular Angiography and Interventions updated guidance for percutaneous coronary intervention in nonhospital, outpatient settings.
The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction, based on the DELIVER phase 3 trial.